Skip to content
A June 21 House hearing on health care costs put a sharp focus on the need for transparency to prevent pharmacy benefit managers (PBMs) […]
House hearing puts focus on need for PBM transparency Read More »
Intellectual property (IP) protections need reform but the current Congress may not have the consensus to achieve these changes, a panel of Capitol Hill
Congress may lack consensus needed for IP reform this year, BIO panelists say Read More »
A proposal to provide the first overhaul of European Union pharma regulation in 20 years takes some positive steps but would still leave a
Asian-Pacific countries and the United States are promoting biotech development through special programs to encourage their domestic industry combined with concerted efforts to attract
How the U.S. and Asia Pacific are collaborating to grow biotech innovation Read More »
The new plan to reform European Union pharmaceutical legislation falls short on data and market protections but includes positive efforts to streamline drug approval
Plan to reform EU pharma law elicits kudos and concerns from BIO experts Read More »
Despite progress from some U.S. trading partners in developing global intellectual property protections that enable innovation, much improvement is needed, according to the Special
USTR calls out countries needing better IP protections in annual report Read More »
Ordinary market mechanisms are inadequate against the emerging public health threat of antimicrobial resistance (AMR), lawmakers and experts agreed at the April 28 hearing
Hearing on public health threat from AMR puts spotlight on PASTEUR Act Read More »
Major leisure-wear label lululemon is now selling men’s and women’s shirts made from Geno’s plant-based nylon, which looks and feels like traditional nylon but
Geno’s plant-based nylon hits global market in lululemon’s new shirt line Read More »
The pace of biotech investment has slowed recently, harming development at the small, new companies that are driving innovation. “Coming down from the heyday
BIO webinar will advise biotech on weathering the slowing investor market Read More »
While animal activists oppose animal testing on moral grounds, the biotech industry knows that alternative technology can provide more accurate and less expensive screening
Biotech wants to reduce animal testing and FDA is now tasked with helping Read More »
